Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 12;109(5):1188–1198. doi: 10.1097/JS9.0000000000000295

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Kaplan–Meier estimate of overall survival (OS). Kaplan–Meier curves show the median OS as the primary endpoint of this study was 9.9 months (95% CI: 7.6–12.2) in the ISP-TACE group compared with 6.3 months (95% CI: 5.4–7.2) in the Sora-TACE group (P=0.016). The survival rates at 3, 6, and 12 months in the ISP-TACE group versus the Sora-TACE group were 84, 73, and 22% versus 81, 41, and 9%, respectively (P=0.016). ISP-TACE group, irradiation stent placement plus transcatheter arterial chemoembolization group; Sora-TACE group, sorafenib plus transcatheter arterial chemoembolization group; TACE, transcatheter arterial chemoembolization.